GlassScriptPhysician profile
Peter J Bullock
NPI 1548299027
$1,785.76
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $462 · 2021: $298 · 2022: $234 · 2023: $273 · 2024: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $519.36 | 2020-2023 | Evenity, Prolia |
| Indivior INC. | $323.53 | 2019-2024 | Sublocade |
| Lilly USA, LLC | $255.22 | 2019-2024 | Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $125.29 | 2023 | Pomalyst |
| Biodelivery Sciences International, INC. | $112.37 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $98.80 | 2021 | |
| Novo Nordisk INC | $81.05 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $64.58 | 2022 | |
| Braeburn INC. | $48.53 | 2024 | Brixadi |
| Otsuka America Pharmaceutical, INC. | $40.53 | 2023 | Nuedexta |
| Genentech USA, INC. | $39.45 | 2020-2021 | |
| Medtronic, INC. | $30.30 | 2022 | |
| Corium, LLC | $17.70 | 2022 | |
| Fidia Pharma USA INC. | $15.25 | 2022 | |
| Pfizer INC. | $13.80 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Bullock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.